Arrowhead Pharmaceuticals Inc (FRA:HDP1)
€ 24.66 4.54 (22.56%) Market Cap: 3.08 Bil Enterprise Value: 2.92 Bil PE Ratio: 0 PB Ratio: 17.54 GF Score: 48/100

Arrowhead Pharmaceuticals Inc Key Opinion Leader Webinar on ARO-APOC3 Transcript

Nov 18, 2020 / 04:30PM GMT
Release Date Price: €59.46 (+3.07%)
Sara Parigian

Good afternoon, and welcome to Part 1 of the 2-part KOL Webinar series hosted by Arrowhead Pharmaceuticals. (Operator Instructions) As a reminder, this conference is being recorded, and a replay will be made available on the Arrowhead website following the event. I would now like to turn the call over to your host, Vince Anzalone, Vice President of Investor Relations at Arrowhead Pharmaceuticals. Please go ahead, sir.

Vincent Anzalone
Arrowhead Pharmaceuticals, Inc. - VP of IR

Thank you, Sara. Next slide, please. So I'm just going to give a quick welcome and introduction. We've got a lot to cover, so we will be quick to get to the content.

Next slide, please. So just reminding everybody that we will be making forward-looking statements today. So please refer to our regulatory filings for the risks to be considered in that regard.

Next slide. So we've got a very good panel today. We're fortunate to have Dr. Christie Ballantyne, who is from the Baylor College of Medicine. He's the Chief of Cardiology and the Chief of Cardiovascular

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot